[Spasmolytic effect of beta-adrenergic drugs. Conservative treatment of urolithiasis].
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000818:Animals; D003085:Colic / Q000188:drug therapy; D004285:Dogs; D004336:Drug Antagonism; D005260:Female; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D008365:Manometry; D009921:Metaproterenol / Q000494:pharmacology; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D012110:Reserpine / Q000494:pharmacology; D013565:Sympatholytics / Q000627:therapeutic use*; D014513:Ureter / Q000187:drug effects / Q000502:physiology; D014514:Ureteral Calculi / Q000188:drug therapy*
D000318:Adrenergic beta-Agonists; D013565:Sympatholytics; D009921:Metaproterenol; D012110:Reserpine; D011433:Propranolol; D007545:Isoproterenol; D010646:Phentolamine
Spasmolyse durch Beta-Adrenergica. Ein Beitrag zur konservativen Behandlung der Urolithiasis.